Table 3.
Effect of MSCs, MSC-derived MVs, and fibroblast-derived MVs on renal morphology and function at day 5 after AKI induction
| Control | AKI | AKI + MV | AKI + MV RNasi | AKI + MSC | AKI + F-MV | AKI + MV sHA | AKI + Try-MV | |
|---|---|---|---|---|---|---|---|---|
| Cast (n/HPF) | 0 | 3.93±1.02 | 0.45±0.4a | 2.86±0.88 | 0.35±0.31a | 3.03±0.32 | 2.38±0.44 | 4.2±2.36 |
| Tubular necrosis (n/HPF) | 0 | 3.27±0.34 | 0.24±0.06a | 3.32±1.5 | 0.38±0.12a | 3.49±0.42 | 2.72±0.64 | 3.78±1.25 |
| BUN (mg/dl) | 30±10 | 145±20 | 60±12a | 135±17 | 52.8±14a | 139±18 | 133±14 | 132±19 |
Injection of 75,000 MSCs, of 15 μg of MSC-derived MVs with or without treatment with sHA or trypsin and 15 mg of fibroblast-derived MVs. Results are expressed as mean ± SD; ANOVA with Dunnet's multicomparison test:
a
P < 0.05 treatments vs untreated AKI.
AKI; AKI untreated with MVs; AKI + MV; AKI treated MSC-derived MVs; AKI + RNase MV; AKI treated with RNase inactivated MSC-derived MVs; AKI + MSC; AKI treated with MSCs; AKI + MV sHA; AKI treated with MSC-derived MVs preincubated with sHA; AKI + F-MV; AKI treated with fibroblast-derived MVs.